TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06163430: A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 330 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT06163430 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06163430 Rescue Dossier →